FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300690054> ?p ?o ?g. }

• W4300690054 endingPage "1809" @default.
• W4300690054 startingPage "1798" @default.
• W4300690054 abstract "Abstract Multiple myeloma is a plasma cell malignancy that is still largely incurable, despite considerable progress in recent years. NF-κB is a well-established therapeutic target in multiple myeloma, but none of the currently available treatment options offer direct, specific pharmacologic targeting of NF-κB transcriptional activity. Thus, we designed a novel direct NF-κB inhibitor (IT848) as a drug candidate with strong potential for clinical translation and conducted comprehensive in vitro and in vivo mechanistic studies in multiple myeloma cell lines, primary multiple myeloma cells, xenograft models, and immunocompetent mouse models of multiple myeloma. Here, we show that IT848 inhibits NF-κB activity through inhibition of DNA binding of all five NF-κB subunits. IT848 treatment of multiple myeloma cell lines and patient samples inhibited proliferation and induced caspase-dependent and independent apoptosis. In addition to direct NF-κB inhibitory effects, IT848 treatment altered the redox homeostasis of multiple myeloma cells through depletion of the reduced glutathione pool, selectively inducing oxidative stress in multiple myeloma but not in healthy cells. Multiple myeloma xenograft studies confirmed the efficacy of IT848 as single agent and in combination with bortezomib. Furthermore, IT848 significantly improved survival when combined with programmed death protein 1 inhibition, and correlative immune studies revealed that this clinical benefit was associated with suppression of regulatory T-cell infiltration of the bone marrow microenvironment. In conclusion, IT848 is a potent direct NF-κB inhibitor and inducer of oxidative stress specifically in tumor cells, displaying significant activity against multiple myeloma cells in vitro and in vivo, both as monotherapy as well as in combination with bortezomib or immune checkpoint blockade." @default.
• W4300690054 created "2022-10-04" @default.
• W4300690054 creator A5003182946 @default.
• W4300690054 creator A5004230969 @default.
• W4300690054 creator A5006878059 @default.
• W4300690054 creator A5010280256 @default.
• W4300690054 creator A5018344902 @default.
• W4300690054 creator A5020046460 @default.
• W4300690054 creator A5023752321 @default.
• W4300690054 creator A5031035765 @default.
• W4300690054 creator A5046495281 @default.
• W4300690054 creator A5056703988 @default.
• W4300690054 creator A5062549382 @default.
• W4300690054 creator A5067820405 @default.
• W4300690054 creator A5073186001 @default.
• W4300690054 creator A5079671192 @default.
• W4300690054 date "2022-10-03" @default.
• W4300690054 modified "2023-10-14" @default.
• W4300690054 title "Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation" @default.
• W4300690054 cites W1539499483 @default.
• W4300690054 cites W1810265271 @default.
• W4300690054 cites W1972779889 @default.
• W4300690054 cites W1973084302 @default.
• W4300690054 cites W1974151922 @default.
• W4300690054 cites W1976731794 @default.
• W4300690054 cites W1989673842 @default.
• W4300690054 cites W1989817110 @default.
• W4300690054 cites W1999574084 @default.
• W4300690054 cites W1999625746 @default.
• W4300690054 cites W2026642838 @default.
• W4300690054 cites W2031626045 @default.
• W4300690054 cites W2040993067 @default.
• W4300690054 cites W2057957370 @default.
• W4300690054 cites W2060725618 @default.
• W4300690054 cites W2067161281 @default.
• W4300690054 cites W2068854551 @default.
• W4300690054 cites W2073598146 @default.
• W4300690054 cites W2076543085 @default.
• W4300690054 cites W2088261928 @default.
• W4300690054 cites W2095147874 @default.
• W4300690054 cites W2099395323 @default.
• W4300690054 cites W2118471749 @default.
• W4300690054 cites W2129778797 @default.
• W4300690054 cites W2145933752 @default.
• W4300690054 cites W2146497768 @default.
• W4300690054 cites W2151117422 @default.
• W4300690054 cites W2152630148 @default.
• W4300690054 cites W2162268427 @default.
• W4300690054 cites W2231563856 @default.
• W4300690054 cites W2256332485 @default.
• W4300690054 cites W2292093022 @default.
• W4300690054 cites W2336509969 @default.
• W4300690054 cites W2344653410 @default.
• W4300690054 cites W2505888563 @default.
• W4300690054 cites W2514649790 @default.
• W4300690054 cites W2518106500 @default.
• W4300690054 cites W2560267087 @default.
• W4300690054 cites W2560469304 @default.
• W4300690054 cites W2610269487 @default.
• W4300690054 cites W2784814303 @default.
• W4300690054 cites W2785091318 @default.
• W4300690054 cites W2890017736 @default.
• W4300690054 cites W2900464803 @default.
• W4300690054 cites W2928218072 @default.
• W4300690054 cites W2941582519 @default.
• W4300690054 cites W2949584172 @default.
• W4300690054 cites W2958797335 @default.
• W4300690054 cites W2962324833 @default.
• W4300690054 cites W2996181407 @default.
• W4300690054 cites W3032950470 @default.
• W4300690054 cites W3047390373 @default.
• W4300690054 cites W3048893185 @default.
• W4300690054 cites W3087735636 @default.
• W4300690054 cites W4220695070 @default.
• W4300690054 cites W4250459881 @default.
• W4300690054 doi "https://doi.org/10.1158/1535-7163.mct-22-0257" @default.
• W4300690054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36190955" @default.
• W4300690054 hasPublicationYear "2022" @default.
• W4300690054 type Work @default.
• W4300690054 citedByCount "3" @default.
• W4300690054 countsByYear W43006900542023 @default.
• W4300690054 crossrefType "journal-article" @default.
• W4300690054 hasAuthorship W4300690054A5003182946 @default.
• W4300690054 hasAuthorship W4300690054A5004230969 @default.
• W4300690054 hasAuthorship W4300690054A5006878059 @default.
• W4300690054 hasAuthorship W4300690054A5010280256 @default.
• W4300690054 hasAuthorship W4300690054A5018344902 @default.
• W4300690054 hasAuthorship W4300690054A5020046460 @default.
• W4300690054 hasAuthorship W4300690054A5023752321 @default.
• W4300690054 hasAuthorship W4300690054A5031035765 @default.
• W4300690054 hasAuthorship W4300690054A5046495281 @default.
• W4300690054 hasAuthorship W4300690054A5056703988 @default.
• W4300690054 hasAuthorship W4300690054A5062549382 @default.
• W4300690054 hasAuthorship W4300690054A5067820405 @default.
• W4300690054 hasAuthorship W4300690054A5073186001 @default.
• W4300690054 hasAuthorship W4300690054A5079671192 @default.
• W4300690054 hasBestOaLocation W43006900541 @default.
• W4300690054 hasConcept C150903083 @default.

• next